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Similar familial risk in multiple sclerosis subgroups 
Introduction 
Multiple sclerosis (MS), a chronic autoimmune disease of the central nervous system (CNS), 
shows great variation in clinical course and severity. This has led to attempts to identify sub-
phenotypes potentially representing independent diseases. One of the hallmarks of MS is the 
presence of so called oligoclonal bands (OCBs) in the cerebrospinal fluid (CSF). OCBs appear on 
electrophoretic or isoelectric separation of CSF proteins and consist of clones of 
immunoglobulin G (IgG) produced by CNS resident plasma cells and plasma blasts1. The 
presence of OCB in CSF indicates intrathecal activity of B-cell believed to contribute to the 
CNS inflammation,2 and thus, the bands are relevant as a diagnostic biomarker in MS.  
However, a subset of patients diagnosed with MS present with no evidence of OCB in the CSF 
(i.e., OCB negative (OCB-)). The proportion varies across the world with the lowest figures in 
Scandinavia (5-10%) and the highest numbers in Asia (50-97%).3,4 In addition, although OCB 
positive (OCB+) and OCB- MS share basic clinical characteristics, OCB- patients have been 
reported to differ significantly also for the other para-clinical tool in MS diagnostics, the MS-
typical lesions seen on magnetic resonance imaging (MRI). OCB- MS patients have less white 
matter lesions and less atrophy in the regional gray matter, basal ganglia and diencephalon5, and 
also differ in the MRI T2 lesion distribution pattern6. Different clinical and epidemiological 
characteristics have also been reported7. Maybe more importantly, the strongest genetic 
association in OCB- MS is not the classical MS risk allele human leukocyte antigen (HLA) 
DRB1*15:01, but HLA DRB1*04:043. Subsequently, whole genome association studies of 
OCB- patients have revealed partly different genetic associations compared to OCB+ MS8. 
Altogether, MRI lesion distribution and HLA associations may well be interpreted to indicate 
that the two MS subtypes have different immune specificities and thus may differ in critically 
important disease mechanisms. 
Materials and methods 
In a previous study, we reported familial risks for MS patients using nationwide registers from 
Sweden9. By linking these data to the Swedish MS registry (SMSreg; http://www.neuroreg.se), we 
were able to find information on OCB status. To be consistent with the majority who only had 
one lumbar puncture and to eliminate possible bias due to effect of treatment or physician 
knowledge, we used the recorded OCB status from the first assessment. Details regarding the 
registers and patient identification are available in the online supplementary material.  
To explore the etiology between OCB- MS and MS, we divided our MS population into four 
groups based on OCB and MS status (Supplementary Table 2) and estimated the risk for a 
relative to a patient diagnosed with OCB- MS to be diagnosed with MS. By defining a person 
diagnosed with OCB-MS as not having MS, we were able to artificially adjust for OCB- MS 
and to estimate to what extent common causes for OBC- MS and MS exist. Our method is 
described and motivated in full in the supplementary methods. Further, to investigate the 
difference in MS risk in OCB- and OCB+ individuals, we applied the same analysis to OCB+ 
individuals.  
Familial risks were measured by odds ratios (ORs) using logistic regression. A robust sandwich estimator 
of standard errors was used to account for non-independence due to familial clustering.   
Results 
In the Swedish MS registry, we were able to identify 4,569 MS patients with known OCB 
status. Among these patients, 525 had ever tested negative for OCB and 37 of these obtained 
OCB+ results at a later time point(s). Excluding these resulted in a total of 488 OCB- patients. 
Demographic information is presented in Supplementary Table 1.  
Results of familial risks of MS in relatives of patients with OCB+/OCB− status are shown in 
Table 1. Significant risks for developing MS were observed among several different 
relationships, such as parents, offspring, and siblings, to OCB- MS patients. The ORs for 
combined first-degree relatives and second-degree relatives to an OCB- MS patient were 5.22 
(95% confidence interval (CI): 3.47-7.87) and 2.59 (95%CI: 1.50-4.45), respectively. The 
corresponding estimates for the relatives to the OCB+ individuals were similar (6.23 (95% CI: 
5.43-7.14) for first-degree relatives and 2.33 (95% CI: 1.87-2.90) for second-degree relatives).  
Discussion 
Our findings showed that despite the diverging genetic and imaging associations, a common 
genetic background seems to be at play in both OCB+ and OCB- MS. To investigate if the 
association could be due to a common autoimmune genetic background, the familial risks for 
two autoimmune conditions, rheumatoid arthritis (RA) and type 1 diabetes (T1D), were 
investigated among relatives to MS patients with different OCB status.10 The risks for first-
degree relatives to OCB- patients to develop RA or T1D were nonsignificant (Supplementary 
Table 3 and 4), arguing that the familial risk of MS in OCB- MS is unlikely due to a common 
autoimmune genetic background. Interestingly, a small but increased risk for RA was found in 
relatives to individuals with OCB+ MS, and amongst all MS patients. The lack of risk in the 
OCB- group might be due to low numbers, but as the majority of the patients in our sample 
were OCB+, our unexpected finding is interesting and opens up for further speculations about 
joint mechanisms in MS and RA. In comparison, though, risks of RA were much smaller than 
the risks of MS. The risk of T1D was, on the other hand, not significant; however, this was still 
in line with the systematic review by Dobson and Giovannoni10 as the registry based studies 
included in their article showed no familial association with T1D. 
One may argue that our sample size of only 488 OCB- MS patients is a limitation of the study. 
However, the main objective of our study was to investigate whether the underlying genetic 
backgrounds differ by estimating the familial risks. With such a modest number of individuals, 
had there been no or very small risks we may not have had sufficient power to detect the risks. 
The estimates in our study were not only significant but also comparable to our previously 
published estimates of MS familial risks9 based on the total Swedish MS population, of which 
90% can be assumed to be OCB+.3 Therefore, we conclude that although the main HLA 
association differs between OCB+ and OCB- MS, the genetic background for the two groups is 
indeed shared. In addition to arguing for homogeneity of the MS entity, our findings support 
OCB- MS to be a relatively homogeneous group itself; as had there been a significant 
“contamination” of MS-mimicking conditions in the OCB- group the familial risk would have 
been affected negatively.  
Furthermore, the influence of course type on our results can be speculated upon. Due to the 
anonymization during the linkage process, it is not possible for us to test this, but looking at 
unlinked data revealed that close to 90% of both the OCB+ and OCB- patients group had a 
relapsing remitting onset, numbers that are very unlikely to influence the results of our study. 
In summary, we found similar familial risks for these two subgroups of MS, arguing against the 
heterogeneity between OCB- subtype and “standard” OCB+ MS. Our study shows how familial 
risks, obtained from population-based data, can have a bearing on problems of taxonomy 
originating from biomarker studies. 
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Table 1. Odds ratios of MS in relatives of patients with OCB- and OCB+ MS a 
Relationship to proband 
Relatives to OCB- patients  
(N, %) 
 
Relatives to OCB+ 
patients 
(N, %) 
 
Relatives to controls  
(N, %) 
 
OR (95%CI)b 
OCB- 
p-valuec  
OCB- 
OR (95%CI) 
OCB+ 
p-valuec  
OCB+ 
First  degree relative 2291 (23, 1.0%) 
18486 (218, 
1.2%) 
45 706 065 (87451, 0.2%) 5.22 (3.47-7.87) <0.0001 6.23 (5.43-7.14) <0.001 
Parent 847 (11, 1.3%) 7314(106, 1.4%) 16 624 232 (36036, 0.2%) 
6.06 (3.34-
10.98) 
<0.0001 6.77 (5.57-8.23) <0.001 
Offspring 789 (2, 0.3%) 5940(25, 0.4%) 16 618 688 (29150, 0.2%) 1.45 (0.36-5.76) 0.60 2.41 (1.60-3.61) <0.001 
Full sibling 655 (10, 1.5%) 5232(87, 1.7%) 12 463 145 (22265, 0.2%) 
8.67 (4.66-
16.13) 
<0.0001 
9.45 (7.61-
11.74) 
<0.001 
Second degree relative 2978 (13, 0.4%) 24162 (79, 0.3%) 67 773 585 (114423, 0.2%) 2.59 (1.50-4.45) 0.001 2.33 (1.87-2.90)d <0.001 
Grandparent 643 (1, 0.2%) 6428(20, 0.3%) 17 3485 87 (39421, 0.2%) 0.68 (0.10-4.86) 0.70 1.37 (0.87-2.17) 0.18 
Grandchild 396 (1, 0.3%) 2820(1, 0.0%) 17 329 180 (16178, 0.1%) 
2.71 (0.41-
18.06) 
0.30 0.38 (0.05-2.69) 0.33 
Uncle/aunt 553 (8, 1.4%) 5400(41, 0.8%) 14 791 484 (40112, 0.3%) 
5.40 (2.70-
10.79) 
<0.0001 2.81 (2.05-3.87) <0.001 
Nephew/niece 1159 (1, 0.1%) 7991(11, 0.1%) 14 761 996 (13858, 0.1%) 0.92 (0.13-6.54) 0.93 1.47 (0.82-2.64) 0.20 
Paternal half-sibling 144 (1, 0.7%) 919(5, 0.5%) 2 009 079 (2772, 0.1%) 
5.06 (0.70-
36.59) 
0.11 3.96 (1.66-9.44) 0.002 
Maternal half-sibling 83 (1, 1.2%) 604(1, 0.2%) 1 533 259 (2082, 0.1%) 
8.97 (1.23-
65.39) 
0.03 1.22 (0.17-8.68) 0.84 
Abbreviations: MS: multiple sclerosis; OCB, oligoclonal band; OCB-, oligoclonal band negative; OCB+, oligoclonal band positive; OR, odds ratio; CI, confidence intervals 
a Affected are the number of relatives diagnosed with MS. Relatives to controls are those relatives to individuals not diagnosed with MS (including OCB-, OCB+ or MS without 
OCB status).  
OR OCB-: the odds of MS in relatives to OCB- patients compared to the odds of MS in relatives to controls; 
OR OCB+: the odds of MS in relatives to OCB+ patients compared to the odds of MS in relatives to controls. 
b A robust (sandwich) estimator of standard errors was used to account for non-independence due to familial clustering. For combined first degree and second degree relatives, 
the non-independence cannot be fully adjusted, however the 95% CI are assumed not to vary much due to the substantial sample size 
c Bonferroni correction was applied to adjust for multiple testing (N = 11, significant level set as P < 0.005) 
d Estimates of 95% CI were not adjusted for familial clustering due to convergence problems. 
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Materials	and	methods	
Swedish	National	Registries	and	study	population	
Several	Swedish	nationwide	registries	were	used	to	establish	the	study	population	through	the	
linkage	of	anonymous	unique	personal	identification	number.	As	described	in	previous	studies	based	
on	Swedish	national	registries	1,2,		we	obtained	data	on	sex	and	date	of	birth	from	the	Total	
Population	Registry	(Statistics	Sweden),	data	on	immigration	and	emigration	from	the	Migration	
Registry	(Statistics	Sweden)	and	data	on	death	date	from	the	Cause	of	Death	Registry	(National	
Board	of	Health	and	Welfare).	The	Multi-Generation	Registry	linked	individuals	to	their	biological	
parents.	Using	this	we	identified	cohorts	of	biological	relatives	with	different	levels	of	shared	genetic	
and	environment	relatedness.	The	flow	chart	of	data	collection	is	shown	in	Supplementary	Figure	1.	
All	registries	were	followed	from	their	start	to	December	31,	2009.		
Classification	of	patients	
The	identification	of	multiple	sclerosis	(MS)	was	the	same	as	in	our	previous	study	2.	In	brief,	a	
person	was	classified	as	an	MS	patient	if	he/she	was	either	in	the	Swedish	Multiple	Sclerosis	Registry	
(SMSreg),	had	an	inpatient	admission	with	MS	diagnosis	(ICD-10	G35,	ICD-9	340	or	ICD-8	340)	,	or	in	
the	Primary	Care	Registry	for	Stockholm	with	ICD-10	G35.		
Patients	with	oligoclonal	band	negative	and	positive	MS	(OCB-	MS	and	OCB+	MS)	were	identified	
through	SMSReg.	CSF	analysis	included	in	this	study	was	done	at	the	neuology	clinics	at	the	time	of	
MS	diagnostic	work-ups.	Routine	CSF	analysis	in	Sweden	typically	includes	detection	of	OCBs	by	
isoelectric	focusing	and	immunoblotting,	IgG	index,	CSF/plasma	albumin	ratio	and	mononuclear	cell	
count.	Patients	were	considered	as	OCB	+	if		two	or	more	IgG	bands	were	detected	in	CSF	and	not	in	
serum		on	electrophoresis	gels		during	isoelectric	focusing	procedure	3.		If	an	individual	had	more	
than	one	CSF	sample	registered,	the	data	from	the	first	sample	was	used.	
The	identifications	of	rheumatoid	arthritis	(RA)	and	type	1	diabetes	were	in	accordance	with	
previous	studies4,5.	A	person	was	classified	as	a	RA	patient	if	he/she	had	at	least	two	separate	
inpatient/outpatient	admissions	for	the	following	ICD	codes:	ICD-10	M05,	M060,	M06.2,	M06.3,	
M06.8,	M06.9,	M12.3;	ICD-9	714.0–2,	714.8,	719.3;	ICD-8	712.10,	712.20,	712.38,	712.39).	The	
diagnostic	validity	of	RA	using	the	Patient	Register	has	been	assessed	previously6.	Type	1	diabetes	
was	defined	with	the	following	ICD	codes:	ICD-10,	E10;	ICD-9,	250;	ICD-8,	250	and	ICD-7,	260.	Since	
earlier	ICD	version	do	not	distinguish	between	type	1	and	type	2	diabetes,	only	those	with	hospital	
discharge	dates	before	the	age	of	20	years	were	classified	as	type	1	diabetes.	
Statistical	analysis		
Due	to	the	lack	of	information	about	OCB	status	in	the	majority	of	MS	patients,	we	could	not	directly	
estimate	the	odds	ratios	(ORs)	of	being	diagnosed	with	MS	in	individuals	who	had	relatives	with	
OCB-	MS	compared	with	those	who	did	not	have	relatives	diagnosed	with	OCB-	MS.	Instead,	we	
selected	a	clearer	sub-population	for	our	estimates.		
We	divided	the	MS	population	into	four	groups	based	on	OCB	and	MS	status	(Supplementary	Table	
1).	In	our	previous	study,	we	estimated	the	ORs	of	being	diagnosed	with	MS	in	individuals	who	had	
relatives	with	MS	(groups	1,	2	and	3)	compared	to	those	without	relatives	diagnosed	with	MS	(group	
4),	which	could	be	approximately	written	as	follows	(under	assumption	that	the	prevalence	of	MS	is	
rare):				
OR(!"!!|!"#$%&'" !") = Pr MS = 1 Relative MS = 1)/ Pr MS = 0 |Relative MS = 1Pr MS = 1 Relative MS = 0)/ Pr MS = 0 |Relative MS = 0=  odds ( MS = 1 Relative group1,2,3)odds MS = 1 Relative group4) 	
To	make	the	ORs	more	comparable	between	OCB-	MS,	OCB+	MS	and	general	MS,	we	assigned	the	
same	denominator	for	each	analysis.	In	details,	we	estimated	the	ORs	of	being	diagnosed	with	MS	in	
individuals	who	had	relatives	with	OCB-	MS	(group	1)	compared	with	those	who	did	not	have	
relatives	diagnosed	with	MS	(group	4).		
OR(!"!!|!"#$%&'" !"#- !") = Pr MS = 1 RelativeOCB-MS = 1)/ Pr MS = 0 |Relative OCB-MS = 1Pr MS = 1 Relative MS = 0)/ Pr MS = 0 |Relative MS = 0=  odds ( MS = 1 Relative group1)odds MS = 1 Relative group4) 	
Similarly,	we	also	estimated	the	ORs	of	being	diagnosed	with	MS	in	individuals	who	had	relatives	
with	OCB+	MS	(group	2)	compared	with	those	who	did	not	have	relatives	diagnosed	with	MS	(group	
4).	OR(!"!!|!"#$%&'" !"#! !")=  Pr ( MS = 1 Relative OCB +  MS = 1)/ Pr MS = 0 |Relative OCB +MS = 1Pr MS = 1 Relative MS = 0)/ Pr MS = 0 |Relative MS = 0=  odds ( MS = 1 Relative group2)odds MS = 1 Relative group4) 	
	
Supplementary	Figure	2	illustrated	the	underlying	mechanisms	between	OCB-	MS	and	MS	in	a	
Directed	Acyclic	Graph	(DAG)6.	Here,	OCB-	MS1	and	MS1	represent	OCB-	MS	and	MS	for	individual	1	
and	OCB-	MS2	and	MS2	represent	OCB-	MS	and	MS	for	the	individual’s	relative	2.	UOCB-	MS	represents	
common	causes	for	OCB-	MS1	and	OCB-	MS2	and	UMS	represents	common	causes	for	MS1	and	MS2.	U1	
represents	common	causes	for	OCB-	MS1	and	MS1	within	individual	1	and	in	the	same	way,	U2	
represents	common	causes	for	OCB-	MS2	and	MS2	within	relative	2.	The	set	of	variable	C	presents	
common	causes	for	OCB-	MS1,	OCB-	MS2,	MS1	and	MS2	that	are	constant	within	the	relative	pair.	This	
can	be	thought	of	as	representing	the	familial	liability	to	both	OCB-	MS	and	MS.	Our	aim	was	to	
explore	to	what	extent	C	exists	by	investigating	the	association	between	MS1	(index	individual)	and	
OCB-	MS2	(relative	of	index	individual).		
By	our	definition,	a	person	diagnosed	with	OCB-	MS	will	be	coded	as	MS	=	0,	and	thereby	artificially	
adjusting	for	OCB-	MS1.	After	this	adjustment,	the	paths	that	may	contribute	to	a	statistical	
association	between	OCB-	MS2	and	MS1	are	
OCB-	MS2              C            MS1		  
OCB-	MS2           C           OCB-	MS1           U1            MS1 
OCB-	MS2           UOCB-	MS       OCB-	MS1									    C         MS1 
OCB-	MS2              UOCB-	MS            OCB-	MS1       U1            MS1	
 The	first	three	paths	presume	the	existence	of	C,	whereas	the	last	one	does	not.	Therefore,	
principally	the	observed	association	between	OCB-	MS2	and	MS1	may	be	explained	by	the	4th	path.	
However,	by	symmetry	UOCB-	MS	is	more	likely	to	influence	OCB-	MS1	and	OCB-	MS2	in	the	same	
direction.	Meanwhile,	for	U1,	which	varies	within	individuals,	it	is	easier	to	think	of	confounders	
affecting	OCB-	MS1	and	MS1	in	the	same	direction	(e.g.,	genetic	or	environment	“vulnerability”).	
Under	this	assumption,	adjusting	for	OCB-	MS1	is	likely	to	induce	a	negative	association	between	
OCB-	MS2	and	MS1.	Hence,	the	fact	that	there	is	a	positive	association	estimated	by	ORs	between	
OCB-	MS2	and	MS1	after	adjustment	for	OCB-	MS1	would	be	a	strong	argument	for	the	existence	of	C.	
A	similar	magnitude	of	estimates	for	ORs	between	the	two	groups	(Table	2	and	Supplementary	Table	
S2)	would	suggest	no	difference	in	familial	risks	for	MS	between	OCB-	and	OCB+	MS	patients.	In	
addition,	we	study	the	association	between	different	types	of	MS	and	RA	(Table	S2).		
	
Statistical	analysis	
We	applied	a	logistic	regression	model	to	estimate	the	above	two	ORs.	A	robust	sandwich	estimator	
of	standard	errors	was	used	to	account	for	non-independence	due	to	familial	clustering.	Bonferroni	
correction	was	applied	to	adjust	for	multiple	testing	(N	=	11,	significant	level	set	as	P	<	0.005).	
Moreover,	we	performed	two	additional	analyses.	First,	to	investigate	if	the	ORs	were	strongly	
confounded	by	age	and	sex	of	individuals,	we	fitted	a	conditional	logistic	regression.	We	estimated	
the	relative	risks	for	MS	for	individuals	with	relatives	diagnosed	with	OCB-	MS	compared	to	up	to	ten	
randomly	selected	individuals	without	relatives	affected	by	MS.	Both	the	individuals	and	their	
relatives	were	matched	on	sex	and	year	of	birth.	To	ensure	equal	follow-up	time	and	equal	
possibility	of	diagnosis,	the	matched	control	was	required	to	be	alive,	reside	in	Sweden	and,	to	
control	for	a	possible	lag	for	inclusion	in	the	Swedish	MS	Registry,	not	diagnosed	with	MS	two	years	
after	the	cases’	diagnosis	date	of	OCB-	MS.	By	this	way	we	avoid	the	assumed	confounding	by	sex	
and	birth	year.		The	results	are	shown	in	Table	S4.	
Finally,	as	a	sensitivity	analysis,	we	repeated	our	main	models	(logistic	regression)	by	defining	OCB+	
MS	as	MS	(redefinition	of	Group	2).	Since	our	sample	consisted	of	90%	OCB+	MS	cases,	the	
association	between	OCB-/OCB+	and	the	full	MS	sample	excluding	only	the	known	OCB-	patients,	did	
not	differ	significantly	from	our	main	estimates	(Data	not	shown).	
	
The	estimated	ORs	in	fact	reflect	the	extent	to	which	shared	familial	factors,	including	both	genetic	
background	and	environmental	factors,	contribute	to	the	association	between	OCB-	MS	and	MS.	
Unfortunately,	we	are	unable	to	evaluate	their	contribution	separately.	On	the	one	hand,	rare	OCB-	
MS	cases	impede	adoption	studies	to	explore	the	extent	to	which	shared	environment	factors	
contribute	to	the	association.	On	the	other	hand,	OCB	status	is	only	detectable	under	primary	
diagnosis	of	MS,	which	hampers	the	estimates	of	correlations	between	OCB-	MS	and	MS	in	terms	of	
underlying	genetic	and	environmental	components.		
	
All	analyses	were	performed	in	SAS	version	9.48	(for	data	management	and	for	conditional	logistic	
regression)	and	Stata	version	13.09	(for	logistic	regression).	STROBE	Statement	was	followed	
(http://strobe-statement.org/fileadmin/Strobe/uploads/checklists/STROBE_checklist_v4_case-
control.pdf).	
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Supplementary	Table	1.	Demographics	and	characteristics	for	the	study	population	of	multiple	
sclerosis	patients	
Group	
Swedish	Multiple	Sclerosis	Registry	 National	
Inpatient	
Registera	
Totala	
OCB	negative	 OCB	positivea	
Unknown	
OCB	status	
Number	of	patients	 488	 4	081	 8	739	 27	078	 28	161	
Mean	age	at	onset,	years	(SD)b	 34.8	(10.1)	 33.2	(10.6)	 33.8	(11.0)	 47.3	(15.2)	 43.8	
Mean	calendar	year	of	birth	 1960	 1962	 1958	 1946	 1947	
Mean	calendar	year	at	onset	 1995	 1995	 1993	 1994	 1991	
Mean	calendar	year	at	CSF	date	 2000	 2000	 2002	 NA	 NA	
Number	of	Female	(%)	 350	(71.7)	 2	899	(71.0)	 6	208	
(71.0)	
17	911	
(66.1)	
18	653	
(66.2)	
Alive	at	time	of	study	(%)	 465	(95.3)	 3	891	(95.3)	 8	149	
(93.2)	
17	801	
(65.7)	
18	872	
(67.0)	
a. Figures	from	Westerlind	et	al,	2014	[12].	
b. The	data	from	the	Swedish	Multiple	Sclerosis	Registry	reflect	the	actual	age	at	onset	determined	by	a	neurologist,	
whereas	the	data	from	the	National	Patient	Register	reflect	the	first	visit	to	a	hospital	(or	alternatively,	to	a	
specialist	if	after	2001)	for	multiple	sclerosis.		
Abbreviations:	OCB,	oligoclonal	band;	SD,	standard	error;	CSF,	cerebrospinal	fluid	
Supplementary	Table	2.	Definition	of	the	four	groups	used	to	estimate	the	odds	ratios	Group	 OCB	Negative	 OCB	Positive	 MS	1	 Yes	 No	 No	2	 No	 Yes	 No	3	 NA	 NA	 Yes	4	 NA	 NA	 No	
OCB:	Oligoclonal	band,	MS:	Multiple	Sclerosis,	NA:	Not	Available	
	
	 	
Supplementary	Table	3.	Risks	of	rheumatoid	arthritis	in	individuals	with	a	first	degree-relative	diagnosed	with	different	types	of	multiple	sclerosis		
Diagnosis	of	the	relative	of	
index	person	
Cases	(affected,	%)	 Controls	(affected,	%)a	
Logistic	regressionb	 Conditional	logistic	regressionc	
Adjusted	OR	(95%CI)	 P-valued	 RR	(95%	CI)	 P-valued	
OCB-	 2291(16,	0.7)	 45	706	065	(311	278,	0.7)	 0.9(0.55-1.48)	 0.68	 0.81	(0.48-1.37)	 0.44	
OCB+	 18	486	(179,	1.0)	 45	706	065	(311	278,	0.7)	 1.3(1.12-1.50)	 0.0006	 1.31(1.12-1.53)	 0.001	
OCB	(OCB+	and	OCB-)	 20	777	(195,	0.9)	 45	706	065	(311	278,	0.7)	 1.25(1.09-1.44)	 0.002	 1.18(1.02-1.37)	 0.03	
All	MS	 113	064	(1770,	1.6)	 49	872	696	(514	548,	1.0)	 1.15(1.10-1.21)	 <.0001	 1.07(1.00-1.14)	 0.06	
a	The	difference	between	first	three	groups	and	the	fourth	group	is	due	to	exclusion	of	the	MS	patients	with	missing	status	on	OCB	in	the	controls	of	the	first	three	groups.	
b		Estimate	of	odds	ratios	(ORs)	was	using	ordinary	logistic	regression	with	adjustment	of	relatives’	age	band.	95%	CI	were	not	adjusted	for	familial	clustering	due	to	convergence	problems.	
c	Estimate	of	relative	risks	(RRs)	was	using	conditional	logistic	regression	which	matched	cases	and	controls	(1:	10)	on	age	and	sex.	95%	CI	were	adjusted	for	familial	clustering	by	using	robust	
sandwich	estimator.	
d	Crude	P-values	before	correction	for	multiple	testing,	which	corresponds	to	95%	confidence	intervals.	Lines	in	bold	indicate	the	P-values	remain	significant	after	Bonferroni	correction	(N	=	2).		
Diagnosis	of	the	relative	of	index	person:	OCB-,	oligoclonal	band	negative	MS;	OCB+,	oligoclonal	band	positive	MS;	OCB,	patients	with	available	information	on	oligoclonal	band;	MS:		patients	
diagnosed	with	multiple	sclerosis	
	 	
Supplementary	Table	4.	Risks	of	type	1	diabetes	in	individuals	with	a	first	degree-relative	diagnosed	with	different	types	of	multiple	sclerosis		
Diagnosis	of	the	relative	of	
index	person	
Cases	(affected,	%)	 Controls	(affected,	%)a	
Logistic	regressionb	 Conditional	logistic	regressionc	
Adjusted	OR	(95%CI)	 P-valued	 RR	(95%	CI)	 P-valued	
OCB-	 2291(41,	1.0)	 45	706	065	(678	287,	1.5)	 0.93	(0.68-1.26)	 0.63	 0.95	(0.68-1.32)	 0.75	
OCB+	 18	486	(306,	1.7)	 45	706	065	(678	287,	1.5)	 0.90	(0.80-1.01)	 0.08	 0.88	(0.78-1.00)	 0.04	
OCB	(OCB+	and	OCB-)	 20	777	(347,	1.7)	 45	706	065	(678	287,	1.5)	 0.91	(0.81-1.01)	 0.07	 0.89	(0.79-1.01)	 0.08	
All	MS	 113	064	(1770,	1.6)	 45	706	065	(678	287,	1.5)	 1.04	(1.00-1.08)	 0.07	 0.99	(0.94-1.05)	 0.82	
a	The	difference	between	first	three	groups	and	the	fourth	group	is	due	to	exclusion	of	the	MS	patients	with	missing	status	on	OCB	in	the	controls	of	the	first	three	groups.	
b		Estimate	of	odds	ratios	(ORs)	was	using	logistic	regression	with	adjustment	of	relatives’	age	band,	sex	and	MS	diagnosis.	95%	CI	were	adjusted	for	familial	clustering.	
c	Estimate	of	relative	risks	(RRs)	was	using	conditional	logistic	regression	which	matched	cases	and	controls	(1:	10)	on	age	and	sex.	95%	CI	were	adjusted	for	familial	clustering	by	using	robust	
sandwich	estimator.	
d	Crude	P-values	before	correction	for	multiple	testing,	which	corresponds	to	95%	confidence	intervals.	Lines	in	bold	indicate	the	P-values	remain	significant	after	Bonferroni	correction	(N	=	2).		
Diagnosis	of	the	relative	of	index	person:	OCB-,	oligoclonal	band	negative	MS;	OCB+,	oligoclonal	band	positive	MS;	OCB,	patients	with	available	information	on	oligoclonal	band;	MS:		patients	
diagnosed	with	multiple	sclerosis	
	
 
	
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Supplementary	Figure	1.	Flow	chart	of	data	collection	in	Swedish	national	registries		
Abbreviations:	OCB	–	oligoclonal	band;	MS	–	multiple	sclerosis	
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Supplementary	Figure	2.	Directed	Acyclic	Graph	to	illustrate	if	familial	factors	exist	that	
contributes	to	OCB-	and	MS.	Abbreviations:	OCB-	oligoclonal	band	negative;	MS	–	multiple	
sclerosis;		
	
	
	
 
 
 
 
 
 
